U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea - 04/23/2021
  1. News & Events for Human Drugs

Virtual | Virtual

Event Title
Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea
April 23, 2021

Date:
April 23, 2021
Time:
9:00 a.m. - 5:00 p.m. ET

DESCRIPTION/SUMMARY

This public workshop is currently being scheduled and planned as a virtual meeting. The Food and Drug Administration, NIAID and CDC are announcing the following public virtual workshop entitled "Development Considerations of Antimicrobial Drugs for the Treatment of Gonorrhea." The purpose of the public virtual workshop is to discuss the nonclinical and clinical pharmacology data and clinical trial design considerations regarding developing antimicrobial drugs for the treatment of gonorrhea.

ABOUT THE PUBLIC WORKSHOP

FDA, NIAID and CDC are announcing a public workshop regarding the development considerations of antimicrobial drugs for the treatment of gonorrhea. The workshop will focus on the current state and nonclinical and clinical trial design considerations regarding antimicrobial drug development for gonorrhea and include the following topic areas:

  • Animal models
  • Clinical pharmacology considerations
  • Trial design considerations for gonorrhea, such as enrollment strategies, choice of comparators and site of infection.

REGISTRATION

This meeting will be held in virtual format only. Registration is required for online attendance and will be available until 5pm on April 21st, 2021

To register for this workshop, visit https://www.eventbrite.com/e/antimicrobial-drugs-for-the-treatment-of-gonorrhea-public-workshop-tickets-146615921167

MEETING MATERIALS

A full agenda will be available before the workshop. All other meeting materials, including speaker slides and transcripts, will be also available here before and after the workshop. Please visit this page for any updates and posting of materials before and after the meeting.

Presentations

Workshop Recording 

Transcript

Session 1

Session 2

ONLINE ATTENDANCE (WEBCAST)

This meeting will be available for online viewing, on the day of the meeting via the following link: https://collaboration.fda.gov/cderond042321/

If you have never attended a Connect Pro event before, test your connection at https://collaboration.fda.gov/common/help/en/support/meeting_test.htm
To get a quick overview of the Connect Pro program, visit https://www.adobe.com/products/adobeconnect.html

EVENT POINT OF CONTACT

Lori Benner and/or Antoinette Ziolkowski, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 6221, Silver Spring, MD 20993-0002, 301-796-1300

Back to Top